Status
Conditions
Treatments
About
To compare pulse oximetry saturation measurements, during normal to low saturation, to saturation measurements made by a multi-wavelength CO-oximeter, taken from arterial blood samples from healthy human subjects.
Full description
The study utilizes a single-site, physiology laboratory (Clinimark) to conduct this Post Market, non-randomized, prospective studies. The goal is to enroll a minimum of fifteen subjects. Subject pool goal of diversity across ethnicity, race and sex of varying skin tones to meet the study design requirements.
The general purpose of Invasive Controlled Desaturation Studies is to support the SpO2 accuracy of the post market pulse oximetry sensors and paired monitor in comparison to reference-standard measurements of blood SaO2 by a CO-oximeter during low saturation conditions. This is achieved through paired observations of SpO2 and SaO2 values over the specified SpO2 accuracy range of 60% to 100% SaO2 of the pulse oximeter on a group of healthy adult volunteers. The fraction of inspired oxygen (FiO2) delivered to test subjects is varied to achieve a series of targeted steady-state saturation periods. Arterial blood samples are periodically taken from an indwelling arterial catheter for use in the comparison. Pulse rate accuracy will be evaluated during the same data collection period as SpO2. Pulse rate will be compared to reference ECG heart rate.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
2 Adult subjects 18 to 50 years of age.
Subject must be willing and able to comply with study procedures and duration.
Subject is a non-smoker or who has not smoked within 2 days prior to the study.
Any gender of any race.
Cleared same day Health Assessment form and health screening.
Cleared physical exam by a licensed physician, physician assistant, or advanced practice nurse (medical exam includes 12-lead ECG, medical history and blood test to show no sickle cell disease present)
Successful Perfusion Index Ulnar/Ulnar+Radial Ratio test showing adequate collateral blood flow.
Exclusion criteria
Subject with sickle cell disease.
Subject is considered as being morbidly obese (defined as BMI >39.5)
Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized.)
Females of childbearing potential, who are pregnant, who are trying to get pregnant or who have a urine test positive for pregnancy on the day of the study
Subjects with COHb levels >3% as assessed by CO-Oximetry during the procedure
tHb < 10 g/dl as assessed by CO-Oximetry during the procedure
MetHb ≥ 2% as assessed by CO-Oximetry during the procedure
Subjects with known respiratory conditions such as:
Subjects with known heart or cardiovascular conditions such as:
Self-reported health conditions as identified in the Health Assessment Form
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal